Compare DSY & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSY | VNRX |
|---|---|---|
| Founded | 2020 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6M | 31.9M |
| IPO Year | 2023 | 2012 |
| Metric | DSY | VNRX |
|---|---|---|
| Price | $3.32 | $0.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 62.7K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,233,511.00 |
| Revenue This Year | N/A | $68.22 |
| Revenue Next Year | N/A | $382.75 |
| P/E Ratio | $16.48 | ★ N/A |
| Revenue Growth | N/A | ★ 59.10 |
| 52 Week Low | $0.17 | $0.17 |
| 52 Week High | $4.03 | $0.94 |
| Indicator | DSY | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 68.03 | 36.92 |
| Support Level | $0.33 | $0.17 |
| Resistance Level | $4.02 | $0.27 |
| Average True Range (ATR) | 0.35 | 0.02 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 39.02 | 17.93 |
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, distribution, and sales of personal care products and other consumer goods. Operating under a consumer-to-manufacturer and merchant (C2M) model, the company integrates online and offline operations to enhance customer engagement, product innovation, and marketing efficiency. Specializing in feminine hygiene products such as sterilized feminine pads, menstrual pants, and related items, Big Tree Cloud leverages its platform to consolidate resources within China's personal care industry while building a consumer community that provides direct feedback and product insights.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.